Hepatitis C virus infection in Western Europe

https://doi.org/10.1016/S0168-8278(99)80379-1Get rights and content

Abstract

Hepatitis C virus (HCV) infection is now recognised as the most common infection causing chronic liver disease in Europe. Approximately 3% of the world population has been infected with HCV, which represents about 170 million chronic carriers at risk of developing serious complications with more than 5 million in Europe alone. In the general population, the prevalence varies geographically from about 0.5% in northern countries to 2% in Mediterranean countries. Among newly detected HCV cases, 40–60% have normal ALT levels, 80% are viraemic, while about 70% of newly detected HCV carriers present histologic liver disease. More than 75% of the cases remain to be identified. The residual risk for transmitting HCV by blood products is at present 1/200 000 units distributed. Intravenous drug users are currently the main risk group. The prevalence rate is about 80% and the yearly incidence varies between 4 and 6%. In haemodialysis patients, the prevalence ranges from 10% to 30% and the incidence from 3% to 7%. The source of infection for the 30% of cases without identifiable risk factor remains to be clarified and appropriate well-controlled case-control studies on large samples are necessary. Further training and information campaigns remain desirable to improve knowledge and awareness among health care professionals.

References (32)

  • L Serfaty et al.

    Risk factors of HCV infection among Elisa-positive blood donors according to RIBA-2 status: a case-control survey

    Hepatology

    (1993)
  • C Conry-Cantilena et al.

    Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

    N Engl J Med

    (1996)
  • S Zeuzem et al.

    Risk factors for the transmission of hepatitis C

    J Hepatol

    (1996)
  • Touzet S, Kraemer L, Colin C, Pradat P, Bailly F, Coppola RC, et al. Prevalence and incidence rates of hepatitis C...
  • MS Sulkowski et al.

    Viral hepatitis among injection drug users

    Viral Hepatitis

    (1998)
  • RS Garfein et al.

    Prevalence and incidence of hepatitis C virus among young adult injection drug users

    J Acq Immune Defic Syndr Hum Retrovirol

    (1998)
  • Cited by (102)

    • Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study

      2015, Clinics and Research in Hepatology and Gastroenterology
      Citation Excerpt :

      About 130–170 million people are chronically infected with the hepatitis C virus (HCV) worldwide[1], with 9 million infected in the United States and Western Europe [2,3].

    • Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow

      2012, International Journal of Drug Policy
      Citation Excerpt :

      Approximately 26% of persons with acute HCV infection are able to spontaneously clear the virus (Micallef, Kaldor, & Dore, 2006) and the remainder become chronically infected, with the consequent risk of HCV-related disease progression: liver fibrosis, cirrhosis and hepatocellular carcinoma. For IDUs, who represent the largest at-risk group in Australia, USA, UK and other Western European countries (Alter et al., 1999; Dore, MacDonald, Law, & Kaldor, 2003; Health Protection Agency, 2009; Trepo & Pradat, 1999), the majority of transmission occurs through the sharing of contaminated injecting equipment, and so there is much opportunity for reinfection among those IDUs who do not use clean needles/syringes on each injecting occasion. There is a lack of consistent evidence regarding the question of whether previous HCV infection confers partial immunity upon re-exposure, and so leads to a lower risk of re-infection compared with the risk of new infection (Corson, Greenhalgh, Palmateer, Weir, & Hutchinson, 2011; Currie et al., 2008; van de Laar et al., 2009); such a lower risk of reinfection was observed in three cohort studies (Farci et al., 1992; Grebely et al., 2006; Mehta et al., 2002).

    View all citing articles on Scopus
    View full text